Jim Cramer's top 10 things to watch in the stock market Tuesday

The article is broadly constructive for risk assets, with U.S. stocks set to open higher as oil prices and bond yields fall, while major AI and IPO activity continues to build. SpaceX is reported as well oversubscribed with $10 billion in institutional orders, OpenAI has confidentially filed for an IPO, and Anthropic finalized a $35 billion debt deal to fund AI expansion. On the corporate side, Alphabet got a $475 price target, Micron is expected to beat guidance, Amazon sold a record C$10 billion bond, and GSK agreed to buy Nuvalent for $10.6 billion.

Analysis

The bigger market issue is not any single IPO; it is the simultaneous arrival of primary equity supply, secondary dilution, and capex-driven financing across the AI stack. That creates a subtle but important rotation risk: capital is being recycled from public megacap balance sheets and late-stage private holders into compute infrastructure and private AI platforms, which can cap multiple expansion even if earnings remain intact. In that setup, the beneficiaries are the asset managers, lenders, and chip suppliers with direct toll-collection on the buildout, while the most exposed names are the mega-cap platforms funding growth through stock issuance rather than cash flow alone.

The credit angle is underappreciated. Large debt packages for private AI players reduce near-term equity dilution, but they also make the private market more rate- and execution-sensitive; if utilization or monetization slips, the pain will surface first in debt markets before it hits public comps. That argues for watching Apollo/Blackstone exposure less as a direct AI upside trade and more as a barometer of whether private AI financing is still being price-insensitive or if spreads are beginning to matter.

On the public side, the market is treating the AI buildout as a winner-take-most story, but the second-order effect may be a broader capital discipline reset. If Google and Apple are forced to spend harder to defend relevance while also signaling shareholder returns, multiple compression risk rises for the entire software/platform complex. In contrast, banks and brokers that intermediate issuance and structured financing could see recurring fee pools with lower earnings volatility than the underlying AI names.

Healthcare looks like a relative shelter rather than a tactical chase. The takeover in biotech reinforces that big pharma still has dry powder and needs replenishment, while the sector’s prior underownership means any sustained rotation can have more price elasticity than crowded AI winners. The key contrarian point: the market is still paying up for AI optionality but has not fully priced in the dilution and supply overhang that can mute returns even in fundamentally strong names over the next 1-3 quarters.

Key Decisions for Investors

• Go long BX as a relative beneficiary of private-market financing and deal flow; use a 1-3 month horizon and prefer weakness near the open on any broad risk-off tape. Risk/reward is attractive if AI private funding stays open, but trim if issuance/funding spreads widen materially.
• Initiate a pairs trade: long GSK / short NUVL on a 2-6 week horizon. The bid for Nuvalent validates M&A appetite, but GSK can convert this into portfolio value more reliably; downside is if broader biotech M&A freezes.
• Reduce or hedge GOOGL into strength over the next 1-2 quarters via call overwrites or a modest put spread. The risk is not business deterioration but dilution and capex intensity compressing per-share upside even if the core franchise performs.
• Buy AMZN on bond-spread normalization or any post-issuance digestion dip, but size it smaller than a pure fundamental long. The financing move is a sign of balance-sheet flexibility, yet the better trade is often the debt ecosystem around it rather than the issuer itself.
• Avoid chasing AAPL until the market proves it will pay for incremental AI announcements; consider a short-dated covered-call approach. The setup is for sentiment to remain capped unless AI features translate into device replacement demand within the next 2-4 quarters.